The combination of mTORC1/2 and PI3Kα inhibition alleviates PI3K pathway reactivation and leads to significant antitumor activity in multiple preclinical xenograft models.

被引：1
|
作者：
Brake, Rachael L. [1 ]
Fabrey, Robyn [2 ]
Szwaya, Jeff [1 ]
Fitzgerald, Michael [1 ]
Iartchouk, Natasha [1 ]
Guo, Xin [2 ]
Kuida, Keisuke [1 ]
Zohren, Fabian [1 ]
Manfredi, Mark [1 ]
机构：
[1] Takeda, Cambridge, MA USA
[2] Takeda Calif, San Diego, CA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2013年 / 12卷 / 11期
关键词：
D O I：
10.1158/1535-7163.TARG-13-C176
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C176
引用
收藏
页数：1
相关论文
共 50 条
  • [31] DUAL PI3K/mTORC1 TARGETING SUPPRESSES HER2+ BRAIN METASTASIS XENOGRAFTS
    不详
    CANCER DISCOVERY, 2016, 6 (08) : 814 - 814
  • [32] The Oncogene Addiction Switch from NOTCH to PI3K Requires Simultaneous Targeting of NOTCH and PI3K Pathway Inhibition in Glioblastoma
    Saito, Norihiko
    Hirai, Nozomi
    Aoki, Kazuya
    Suzuki, Ryo
    Fujita, Satoshi
    Nakayama, Haruo
    Hayashi, Morito
    Ito, Keisuke
    Sakurai, Takatoshi
    Iwabuchi, Satoshi
    CANCERS, 2019, 11 (01):
  • [33] Recent Developments in Anti-Cancer Agents Targeting PI3K, Akt and mTORC1/2
    Dienstmann, Rodrigo
    Rodon, Jordi
    Markman, Ben
    Tabernero, Josep
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2011, 6 (02) : 210 - 236
  • [34] The antitumor effects of PI3K beta inhibitors in PTEN negative prostate cancer are enhanced by inhibition of reactivated PI3K alpha signaling
    Schwartz, Sarit
    Carver, Brett S.
    Wongvipat, John
    Rodrik-Outmezguine, Vanessa
    Stanchina, Elisa D.
    Trigwell, Cath
    Barry, Simon
    Baselga, Jose
    Chandarlapaty, Sarat
    Scher, Howard I.
    Sawyers, Charles L.
    Rosen, Neal
    CANCER RESEARCH, 2014, 74 (19)
  • [35] The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth (vol 35, pg 1902, 2016)
    Bago, Ruzica
    Sommer, Eeva
    Castel, Pau
    Crafter, Claire
    Bailey, Fiona P.
    Shpiro, Natalia
    Baselga, Jose
    Cross, Darren
    Eyers, Patrick A.
    Alessi, Dario R.
    EMBO JOURNAL, 2016, 35 (20): : 2263 - 2263
  • [36] Combination of ShuangDan Capsule and Sorafenib Inhibits Tumor Growth and Angiogenesis in Hepatocellular Carcinoma Via PI3K/Akt/mTORC1 Pathway
    Ding, Wenbo
    Chen, Xiuwei
    Yang, Licheng
    Chen, Yaping
    Song, Jie
    Bu, Weiquan
    Feng, Bin
    Zhang, Meng
    Luo, Yi
    Jia, Xiaobin
    Feng, Liang
    INTEGRATIVE CANCER THERAPIES, 2022, 21
  • [37] Short-term PI3K Inhibition Prevents Breast Cancer in Preclinical Models
    Ku, Amy T.
    Young, Adelaide I. J.
    Ibrahim, Ahmed Atef
    Bu, Wen
    Jiang, Weiyu
    Lin, Meng
    Williams, Laterrica C.
    McCue, Bryant Lee
    Miles, George
    Nagi, Chandandeep
    Behbod, Fariba
    Li, Yi
    CANCER PREVENTION RESEARCH, 2023, 16 (02) : 65 - 73
  • [38] Short-term PI3K inhibition prevents breast cancer in preclinical models
    Ku, Amy T.
    Young, Adelaide
    Ibrahim, Ahmed A.
    Bu, Wen
    Jiang, Weiyu
    Lin, Meng
    Williams, Laterrica C.
    McCue, Bryant
    Miles, George
    Nagi, Chandandeep
    Behbod, Fariba
    Li, Yi
    CANCER PREVENTION RESEARCH, 2023, 16 (01)
  • [39] Combination of ShuangDan Capsule and Sorafenib Inhibits Tumor Growth and Angiogenesis in Hepatocellular Carcinoma Via PI3K/Akt/mTORC1 Pathway
    Ding, Wenbo
    Chen, Xiuwei
    Yang, Licheng
    Chen, Yaping
    Song, Jie
    Bu, Weiquan
    Feng, Bin
    Zhang, Meng
    Luo, Yi
    Jia, Xiaobin
    Feng, Liang
    INTEGRATIVE CANCER THERAPIES, 2022, 21
  • [40] Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
    LoRusso, Patricia Mucci
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) : 3803 - +
12345